Risk/Benefit Assessment, Advantages Over Other Drugs and Targeting Methods in the Use of Deferiprone as a Pharmaceutical Antioxidant in Iron Loading and Non Iron Loading Conditions

REFERENCES

• Denisov ET, Afanas’ev IB. Oxidation and Antioxidants in Organic Chemistry and Biology. Boca Raton: CRC Press, Taylor and Francis group; 2005.
   Google Scholar
• Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. 2009; E1:161–178.
   Google Scholar
• Lodi R, Hart PE, Rajagopalana B, Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001; 49(5):590–596.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Michaelides Y, Kontos C, Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008; 32(1–2):17–28.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005; 12(23):2663–2681.
   PubMed Web of Science ®Google Scholar
• Wallis LI, Paley MN, Graham JM, MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging. 2008; 28(5):1061–1067.
   Google Scholar
• Kontoghiorghes GJ, Jackson MJ, Lunec J. In vitro screening of iron chelators using models of free radical damage. Free Radic Res Commun. 1986; 2(1–2):115–124.
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Bunce T, Bruckdorfer KR. Differentiation of the therapeutic and toxicological effects of iron and copper chelating drugs in relation to free radical toxicity. Toxicol Lett. 1995; 78:48–49.
   Google Scholar
• Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P. The iron chelators desferrioxamine and 1-alkyl-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacylin synthesis in vitro. Biochem J. 1988; 254(1):239–244.
   PubMedGoogle Scholar
• Barradas MA, Jeremy J, Kontoghiorghes GJ, Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity. FEBS Lett. 1989; 245(1–2):105–109.
   Google Scholar
• Anderson LJ, Wonke B, Prescott E, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002; 360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006; 107(9):3733–3737.
   PubMed Web of Science ®Google Scholar
• Platis O, Anagnostopoulos G, Farmaki K, Glucose metabolism disorders improvement in patients with thalassaemia major after 24–36 months of intensive chelation therapy. Pediatr Endocrinol Rev. 2004; 2(Suppl 2):279–281.
   PubMedGoogle Scholar
• Tanner MA, Galanello R, Dessi C, A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007; 115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rotig A, Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007; 110(1):401–408.
   PubMed Web of Science ®Google Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy. J Am Soc Nephrol. 2007; 18:329A.
   Google Scholar
• Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol. 2007; 18:57–58A.
   Google Scholar
• Chang YH, Shaw CF, Hsieh KH, Lu PJ. A novel finding. Use of deferiprone in iron overload of a Fanconi anemia patient resolving bone marrow failure. Proceedings of the 17th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases Related to Metal and Free Radical Imbalance and Toxicity, Shenzen, China, November 2007; Abstract Book; 47
   Google Scholar
• Forni GL, Balocco M, Cremonesi L, Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008; 23(6):904–907.
   PubMed Web of Science ®Google Scholar
• Evans RW, Sharma M, Ogwang W, The effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today. 1992; 28(Suppl A):19–23.
   Google Scholar
• Vreugdenhil G, Kontoghiorghes GJ, Van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol. 1991; 9(1):35–40.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004; 11(16):2161–2183.
   PubMed Web of Science ®Google Scholar
• Fredenburg AM, Sethi RK, Allen DD, Yokel RA. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-,1,2-diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology. 1996; 108(3):191–199.
   PubMed Web of Science ®Google Scholar